Selected article for: "simplex virus and virus type"
Author: Zeng, Zhengyang; Zhang, Runhong; Hong, Wei; Cheng, Yuting; Wang, Huijuan; Lang, Yange; Ji, Zhenglin; Wu, Yingliang; Li, Wenxin; Xie, Youli; Cao, Zhijian
Title: Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1
  • Document date: 2018_1_1
    • ID: zilqyfjl_1
    Snippet: Herpes simplex virus type I (HSV-1) is one of the most common human pathogens, infecting 70-90% of the human population [1] . Humans are the only natural hosts of HSV, and HSV infection is almost exclusively limited to epithelial cells and peripheral nervous system (PNS) neurons [2] . HSV can cause diseases ranging from mild conditions to lethal infections, including mucocutaneous lesions in labialis and skin, herpes keratitis and herpes encephal.....
    Document: Herpes simplex virus type I (HSV-1) is one of the most common human pathogens, infecting 70-90% of the human population [1] . Humans are the only natural hosts of HSV, and HSV infection is almost exclusively limited to epithelial cells and peripheral nervous system (PNS) neurons [2] . HSV can cause diseases ranging from mild conditions to lethal infections, including mucocutaneous lesions in labialis and skin, herpes keratitis and herpes encephalitis [3] . Most of the licensed treatments are based on nucleoside analogues such as acyclovir, valacyclovir and famciclovir. However, current treatments are unable to prevent establishment of latency and reactivation of latent virus [4] . Due to the drug resistance, side effects, and poor bioavailability associated with current treatments and the lack of an effective HSV-1 vaccine, the discovery and development of novel anti-HSV-1 agents are still urgent.

    Search related documents:
    Co phrase search for related documents
    • anti agent and development discovery: 1, 2
    • anti agent and drug resistance: 1, 2, 3
    • anti agent and effective vaccine: 1, 2
    • common human pathogen and current treatment: 1, 2
    • common human pathogen and drug resistance: 1
    • common human pathogen and effective vaccine: 1
    • common human pathogen and famciclovir valacyclovir: 1
    • current treatment and development discovery: 1, 2, 3, 4, 5
    • current treatment and drug resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • current treatment and effective vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • current treatment and effective vaccine lack: 1, 2
    • current treatment and effective vaccine lack current treatment: 1, 2
    • current treatment and epithelial cell: 1, 2, 3, 4, 5, 6, 7
    • development discovery and drug resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • development discovery and effective vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • drug resistance and effective vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • drug resistance and effective vaccine lack: 1
    • drug resistance and epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • effective vaccine and epithelial cell: 1, 2, 3, 4, 5